Literature DB >> 22272610

Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease.

Chenyou Sun1, Xiaoming Ou, Jerry M Farley, Craig Stockmeier, Steven Bigler, Roberta Diaz Brinton, Jun Ming Wang.   

Abstract

More than a third of Alzheimer's disease (AD) patients show nigrostriatal pathway disturbances, resulting in akinesia (inability to initiate movement) and bradykinesia (slowness of movement). The high prevalence of this dysfunction of dopaminergic neuron in the nigrostriatal pathway in AD suggests that the risk factors for AD appear also significant risk factors for substantia nigra pars compacta (SNpc) lesions. Previously, we have demonstrated that allopregnanolone (APα) promotes neurogenesis and improves the cognitive function in a triple transgenic mouse model of AD (3xTgAD). In this study, we sought to exam 1) the SNpc lesions in 3xTgAD mice and 2) the impact of APα on promoting the regeneration of new dopaminergic neurons in SNpc of the 3xTgAD mice. The number of Nissl-stained total neurons, tyrosine hydroxylase (TH) positive neurons, and BrdU/TH double positive newly formed neurons were analyzed with unbiased stereology. In the SNpc of 3xTgAD mice, TH positive neurons was 47+- 18 % (p = 0.007), total neurons was 62 +-11.6 % (p = 0.016), of those in the SNpc of non-Tg mice, respectively. APα treatment increased the TH positive neurons in the SNpc of 3xTgAD mice to 93.2 +- 18.5 (p = 0.021 vs. 3xTgAD vehicle) and the total neurons to 84.9+- 6.6 (p = 0.046 vs. 3xTgAD vehicle) of non-Tg mice. These findings indicate that there is a loss of neurons, specifically the TH positive neurons in SNpc of 3xTgAD mice, and that APα reverses the lesion in SNpc of 3xTgAD by increasing the formation of new TH neurons.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22272610      PMCID: PMC3348519          DOI: 10.2174/156720512800492567

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  69 in total

Review 1.  Neurogenesis in substantia nigra of parkinsonian brains?

Authors:  Oscar Arias-Carrión; Elizabeth Yamada; Nils Freundlieb; Miriam Djufri; Lukas Maurer; Guido Hermanns; Bastian Ipach; Wei-Hua Chiu; Corinna Steiner; Wolfgang H Oertel; Günter U Höglinger
Journal:  J Neural Transm Suppl       Date:  2009

2.  Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).

Authors:  Martin Ramsden; Linda Kotilinek; Colleen Forster; Jennifer Paulson; Eileen McGowan; Karen SantaCruz; Aaron Guimaraes; Mei Yue; Jada Lewis; George Carlson; Michael Hutton; Karen H Ashe
Journal:  J Neurosci       Date:  2005-11-16       Impact factor: 6.167

Review 3.  Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective.

Authors:  Khalid Iqbal; Inge Grundke-Iqbal
Journal:  J Alzheimers Dis       Date:  2006       Impact factor: 4.472

4.  Restricted proliferation and migration of postnatally generated neurons derived from the forebrain subventricular zone.

Authors:  M B Luskin
Journal:  Neuron       Date:  1993-07       Impact factor: 17.173

5.  The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression.

Authors:  Jun Ming Wang; Patrick B Johnston; Bret Gene Ball; Roberta Diaz Brinton
Journal:  J Neurosci       Date:  2005-05-11       Impact factor: 6.167

6.  Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease.

Authors:  Pamela J McMillan; Sylvia S White; Allyn Franklin; J Lynne Greenup; James B Leverenz; Murray A Raskind; Patricia Szot
Journal:  Brain Res       Date:  2010-12-11       Impact factor: 3.252

7.  Decreased susceptibility to oxidative stress underlies the resistance of specific dopaminergic cell populations to paraquat-induced degeneration.

Authors:  A L McCormack; J G Atienza; J W Langston; D A Di Monte
Journal:  Neuroscience       Date:  2006-05-04       Impact factor: 3.590

Review 8.  Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease.

Authors:  C-X Gong; K Iqbal
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

9.  Changes in expression of the neuropeptide Y Y1 receptor gene in the medial amygdala of transgenic mice during pregnancy and after delivery.

Authors:  Alessandra Oberto; Mariangela Serra; Maria Giuseppina Pisu; Giovanni Biggio; Carola Eva
Journal:  J Neurochem       Date:  2002-09       Impact factor: 5.372

10.  Pathologic correlates of dementia in Parkinson's disease.

Authors:  H C Chui; J A Mortimer; U Slager; C Zarow; W Bondareff; D D Webster
Journal:  Arch Neurol       Date:  1986-10
View more
  17 in total

Review 1.  Neurotrophic natural products: chemistry and biology.

Authors:  Jing Xu; Michelle H Lacoske; Emmanuel A Theodorakis
Journal:  Angew Chem Int Ed Engl       Date:  2013-12-18       Impact factor: 15.336

Review 2.  Neurosteroids as regenerative agents in the brain: therapeutic implications.

Authors:  Roberta D Brinton
Journal:  Nat Rev Endocrinol       Date:  2013-02-26       Impact factor: 47.564

3.  Age-related changes in neuroactive steroid levels in 3xTg-AD mice.

Authors:  Donatella Caruso; Anna M Barron; Meghan A Brown; Federico Abbiati; Paloma Carrero; Christian J Pike; Luis M Garcia-Segura; Roberto C Melcangi
Journal:  Neurobiol Aging       Date:  2012-11-02       Impact factor: 4.673

Review 4.  Monoaminergic neuropathology in Alzheimer's disease.

Authors:  Goran Šimić; Mirjana Babić Leko; Selina Wray; Charles R Harrington; Ivana Delalle; Nataša Jovanov-Milošević; Danira Bažadona; Luc Buée; Rohan de Silva; Giuseppe Di Giovanni; Claude M Wischik; Patrick R Hof
Journal:  Prog Neurobiol       Date:  2016-04-12       Impact factor: 11.685

Review 5.  Neuroregeneration and dementia: new treatment options.

Authors:  Smaranda Ioana Mitran; Bogdan Catalin; Veronica Sfredel; Tudor-Adrian Balseanu
Journal:  J Mol Psychiatry       Date:  2013-07-17

6.  Mitochondria modulatory effects of new TSPO ligands in a cellular model of tauopathies.

Authors:  Amandine Grimm; Imane Lejri; François Hallé; Martine Schmitt; Jürgen Götz; Frederic Bihel; Anne Eckert
Journal:  J Neuroendocrinol       Date:  2019-10-13       Impact factor: 3.627

7.  Allopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons and motor performance in an MPTP-lesioned mouse model of Parkinson's disease.

Authors:  Samuel O Adeosun; Xu Hou; Yun Jiao; Baoying Zheng; Sherry Henry; Rosanne Hill; Zhi He; Amar Pani; Patrick Kyle; Xiaoming Ou; Thomas Mosley; Jerry M Farley; Craig Stockmeier; Ian Paul; Steven Bigler; Roberta Diaz Brinton; Richard Smeyne; Jun Ming Wang
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

Review 8.  Allopregnanolone and neurogenesis in the nigrostriatal tract.

Authors:  Jun Ming Wang
Journal:  Front Cell Neurosci       Date:  2014-08-12       Impact factor: 5.505

9.  1,25(OH)2D3 Alleviates Aβ(25-35)-Induced Tau Hyperphosphorylation, Excessive Reactive Oxygen Species, and Apoptosis Through Interplay with Glial Cell Line-Derived Neurotrophic Factor Signaling in SH-SY5Y Cells.

Authors:  Ching-I Lin; Yi-Chen Chang; Ning-Jo Kao; Wei-Ju Lee; Tzu-Wen Cross; Shyh-Hsiang Lin
Journal:  Int J Mol Sci       Date:  2020-06-13       Impact factor: 5.923

Review 10.  Neurosteroid Metabolites of Gonadal Steroid Hormones in Neuroprotection: Implications for Sex Differences in Neurodegenerative Disease.

Authors:  Ari Loren Mendell; Neil James MacLusky
Journal:  Front Mol Neurosci       Date:  2018-10-05       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.